Prophylactic Anticoagulation for Preventing Deep Vein Thrombosis After Total Hip Arthroplasty

Phase 2

Completed

• Conditions: Deep Vein Thrombosis
• Interventions: Other: prophylactic anticoagulation

• Registration Number: NCT01446887
• Lead Sponsor: JIANG Qing

Brief Summary

Deep vein thrombosis (DVT) remains a life-threatening complication of arthroplasty. It remains controversial for anticoagulation strategies after total hip arthroplasty (THA). A randomized double-blind study was conducted to determine whether prophylactic anticoagulation was efficient reduce DVT after THA. subjects who underwent uncemented THA were assigned to prophylactic anticoagulation group or non- prophylactic anticoagulation group. Patients were followed up 3 months later after surgery. DVT was tested by contrast venography. Investigator also used logistic regression analysis with variable selection for obtaining the prediction model of DVT. DVT after THA was affected by personal (age) and clinical factors (mechanical compression, duration of surgery). THA with short duration of surgery did not require prophylactic anticoagulation.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-01
• Primary Completion: 2010-12
• Study Completion: 2011-02
• Study First Submitted: 2011-09-28
• Status Verified: 2011-10
• Study First Submitted QC: 2011-10-04
• Study First Posted: 2011-10-05
• Last Update Submitted: 2011-10-08
• Last Update Posted: 2011-10-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Primary total hip arthroplasty

Exclusion Criteria

• Revision hip replacement, total knee replacement, revision knee replacement, semi-hip replacement and cemented THR were excluded.
• Coagulation related disease and cancer were excluded either.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
prophylactic anticoagulation	prophylactic anticoagulation	prophylactic anticoagulation by rivaroxaban

Primary Outcome Measures

Name	Time	Method
all cause DVT	7 days	deep-vein thrombosis nonfatal pulmonary embolism, or death

Secondary Outcome Measures

Name	Time	Method
Major DVT	7 days	major venous thromboembolism (proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death from venous thromboembolism)

Trial Locations

Locations (1)

The Center of Diagnosis and Treatment for Joint Disease, Drum Tower Hospital; 🇨🇳 Nanjing, Jiangsu, China